Industry Supported Session

Lunch ’n Learn: New Advances in the Treatment of General Myasthenia Gravis: Expanding the use of Targeted Therapy

Tuesday, June 6, 2023

12:00 PM – 1:30 PM MST

Location:H-M2: Alhambra

Audience:

Adult Neurologist, Neuroradiologist, Neurophysiologist, Resident, Fellow, Nurses with interest in topic

Learning Level:

Basic (Resident, New Information), Intermediate (Practicing Physician), Advanced (Special Interest, Higher Level Discussion)

Learning Format:

Case studies, Lecture/plenary method, Question and answer sessions

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Leader, Health Advocate, Professional

Faculty(s)

SC

Sameer Chhibber

Review current management goals for gMG. Review of the gMG mechanism of disease, the role of complement and how in the CHAMPION MG study, Ravulizumab demonstrated Efficacy and Safety in the treatment of AChR anti-body positive gMG disease. Translating evidence into the real-world management of the “earlier” gMG patient.

This program was developed by the CNSF and Alexion Pharma Canada and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Learning Objectives:

Define gMG management goals and current strategies
Define the role of complement in the pathophysiology of gMG
Evaluate the Efficacy and Safety of Ravulizumab in the treatment of (AchR) anti-body positive generalized Myasthenia Gravis
Understand how the clinical evidence can be applied in the clinical setting through case discussion

Presentations:

12:00 PM – 1:00 PM MST

New Advances in the Treatment of General Myasthenia Gravis: Expanding the use of Targeted Therapy -Presentation will include multiple reflections and incorporate an interactive discussion on the practical management of patients
Faculty: Sameer Chhibber
1:00 PM – 1:30 PM MST

Wrap up & Specific Course Evaluation